Department of Internal Medicine

Division of Hematology and Oncology

Articles, Patents and Intellectual Property

Adsay NV, Dergham ST, Koppitch FC, Dugan MC, Mohamed AN, Vaitkevicius VK, and Sarkar FH Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma. Pancreas 18(2): 111-6. 1999.

Ahmed I, Al-Katib A, Beck FWJ, Mohammad RM. Sequential treatment of a resistant CLL-patient with Bryostatin 1 followed by 2-Chlorodeoxyadenosine: Case Report. Clinical Cancer Research, (in press).

Ahmed S, Shurafa MS, Bishop CR and Varterasian M. WaldenstromÕs macroglobulinemia in young African-American adults. Am J Hematol 60(3): 229-30. 1999.

Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, and. Sarkar FH.  Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer 34(1): 12-9. 1999

Al-Sarraf M, LeBlanc M, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:  phase III randomized intergroup study. 0099. Classic Papers & Current Comments, 10/13/99.

Aref A, Mohammad R, Yudelev M, Choudhuri R, Strowbridge A, Orton C, and. Al-Katib A. Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-HodgkinÕs lymphoma cell lines. Radiat Oncol Investig 7(3): 158-62, 1999.

Aref A, Narayan S, Tekyi-Mensah S, Varterasian M, Dan M, Eilender D, Karanes C, and. Al-Katib A. Value of radiation therapy in the management of chemoresistant intermediate grade non-HodgkinÕs lymphoma. Radiat Oncol Investig 7(3): 186-91, 1999.

Aref A, Yudelev M, Mohammad R., Choudhuri R, Orton C, and Al-Katib A. Neutron and photon clonogenic survival curves of two chemotherapy resistant human intermediate-grade non-Hodgkin lymphoma cell lines. Int J Radiat Oncol Biol Phys 45(4): 999-1003, 1999.

Aslakson CJ, Lee G, Gilman-Sachs A, Kucuk O, Beaman KD. Expression of Regeneration and Tolerance Factor on B Cell Chronic Lymphocytic Leukemias: A Possible Mechanism for Escaping Immune Surveillance. Am J Hematol 61:46-52, 1999.

Baynes R, Dansey R, Klein J, Karanes C, Abella E, Cassells L, Wei W, Galy A, Wood G, and Peters W. High dose chemotherapy and peripheral blood progenitor cell transplantation in patients with breast cancer.: (in press).

Baynes RD, Dansey RD, Klein JK, Peters WP.  High dose chemotherapy and peripheral blood progenitor cell transplantation in patients with breast cancer.  The Oncologist (In Press).

Baynes RD, Zielinsky I, Dansey RD.  Large volume leukapheresis.  Cobe Monograph (In Press).

Bearman S, Vredenburgh J, Cagnoni P, Shpall E, Nieto Y, Ross M, Peters W, and Jones R. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. Bone Marrow Transplant 24(5): 491-5, 1999.

Beck FWJ, Al-Katib AM, Ahmad I, Wall NR, Liu KZ, Mantsch HH, Mohammad RM.  Effect of bryostatin 1 on nucleoside transporters in WSU-CLL cells: implications for enhanced sensitivity to 2-chlorodeoxyadenosine. Int J Mol Med, (in press).

Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, and Griffin T.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2): 485-93, 1999.

Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, and Eliason JF.  Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 27(3): 425-32. 1999.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G., Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, and Wilding G.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate- specific antigen working group. J Clin Oncol 17(11): 3461-7, 1999

Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, and Bloomfield CD. Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. J Clin Oncol 17(12): 3767-3775, 1999.

Carter DL, Marks LB, Bean JM, Broadwater G, Hussein A, Vredenburgh JJ, Peters WP, and Prosnitz LR. Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue. J Clin Oncol 17(3): 887-93, 1999.

Chandra A, and Eilender D.  Uncommon sites of presentation of hematologic malignancies. Case 1: localized primary non-HodgkinÕs lymphoma of the patella.  J Clin Oncol 17(5): 1640-2, 1999.

Chandrasekar PH, Abraham OC, Klein J, Alangaden G, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R.  Low infectious morbidity following intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer.  Annals of Internal Medicine, 1999.

Chen C, Karanes C, Pettit GR, and Chen B.  Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitors induced cytochrome c-dependent apoptosis.  Cancer Res.  (in press).

Cher ML, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, and Wood Jr DP,  Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res 5(9): 2421-5, 1999.

Chomchai JS, Du W, Sarkar FH, Li YW, Jacobs JR, Ensley JF, Sakr W, and Yoo GH.  Prognostic significance of p53 gene mutations in laryngeal cancer.  Laryngoscope 109(3): 455-9, 1999.

Corbett TH, Panchapor C, Polin L, Lowichik N, Pugh S, White K, Kushner J, Meyer J, Czarnecki J, Chinnukroh S, Edelstein M, LoRusso P, Heilbrun L, Horwitz JP, Grieshaber C, Perni R, Wentland M, Coughlin S, Elenbaas S, Philion R, and Rake J. Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs 17(1): 17-27, 1999.

Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, and Bloomfield CD. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 93(11): 3931-9, 1999.

Danam-Prapurna RD, Lu MH, Lewis SM, Djuric Z, Leake JE, and Hart RW.   Modulation of peroxidation potential by age and dietary fat in different tissues of rats.  Mechanisms of Aging and Development, 110:87-99, 1999.

Davis, J.N., Kucuk, O., Sarkar F.H. Genistein inhibits NF-kappaB activation in prostate cancer cells. Nutr Cancer (in press).

Djuric Z, Uhley VE, Depper JB, Brooks KM, Lababidi S, and Heilbrun LK.  A clinical trial to selectively change dietary fat and/or energy intake in women: the WomenÕs Diet Study.  Nutr Cancer 34(1): 27-35. 1999.

Duanmu Z, Dunbar J, Falany CN, and Runge-Morris M. Induction of Rat Hepatic Aryl Sulfotransferase (SULT1A1) Gene Expression by Triamcinolone Acetonide: Impact on Minoxidil-Mediated Hypotension. Toxicol. Appl. Pharmacol, (in press).

Eliason JF, Greway A., Tare N, Inoue T, Bowen S, Dar M, Yamasaki M, Okabe M, and Horii I.  Extended activity in cynomolgus monkeys of a granulocyte-colony stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells 18: (in press).

Ellis GK, Green S, Livingston RB, Kraut MJ, Pierce HI, Paradelo JC, Taylor SA, and Martino S. ÔNeo-FACÕ (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor- prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study. Am J Clin Oncol 22(5): 446-9, 1999.

Evelhoch JL.  Key factors in the acquisition of contrast kinetic data for oncology.  J Magn Reson Imaging 10(3): 254-9, 1999.

Farthing D, Sica D, Abernathy C, Fakhry I, Roberts JD, Abraham DJ, and Swerdlow P.  High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells and urine. J Chromatogr B Biomed Sci Appl 726(1-2): 303-7, 1999.

Fernandez-Madrid F, VandeVord PJ, Yang X, Karvonen RL, Simpson PM, Kraut MJ, Granda JL, and Tomkiel JE.  Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res 5(6): 1393-400, 1999.

Fontana JA, Dawson M, Licid M, Rishi AK, Zhang Y, Hsu CA, Liu J, Peterson V, Hobbs P, Chao WR, Shroot B, and Reichert U.  Identification of a unique binding protein for a Novel Retnoid Inducing Cellular Apoptosis. Int J Cancer: (in press).

Foster BJ, Fortuna M, Media J, Wiegand RA and Valeriote FA.  Cryptophycin-1 cellular levels and effects in vitro using L1210 cells. Invest New Drugs 16: 199 Ð 204, 1999.

Gadgeel SM, Ramalingam S, Cummings G, Kraut MJ, Wozniak AJ, Gaspar LE,  and Kalemkerian GP. Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program. Chest 115(5): 1232-6, 1999.

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, and Rai KR.  Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res 23(8): 709-18, 1999.

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, and Rai KR.  Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leuk Res 23(9): 817-26, 1999.

Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, and Howell SB.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17(10): 3110-6, 1999.

Gopalakrishna R, Gundimeda U, Fontana JA, and Clarke R.  Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status. Cancer Lett 136(2): 143-51, 1999.

Grieco PA, Morre DJ, Corbett TH, Valeriote FA.  Therapeutic Quassinoid Preparations with Antineoplastic, Antiviral, and Herbistatic Activity.  Patent Number US 5,965,493 File Date 5/1/1997.  Issue Date 10/12/1999.

Guan HP, Ksebati MB, Cheng YC, Drach JC, Kern ER, Zemlicka J.   Spiropentane mimics of nucleosides: Analogues of 2Õ-deoxyadenosine and 2Õ-deoxyguanosine.  Synthesis of all stereoisomers, isomeric assignment, and biological activity.  J. Org. Chem., (in press).

Gururajanna B, Al-Katib AA, Li YW, Aranha O, Vaitkevicius VK, and Sarkar FH.  Molecular effects of taxol and caffeine on pancreatic cancer cells. Int J Mol Med 4(5): 501-7, 1999.

Hryniuk W. Importance of chemotherapy scheduling: pieces of the puzzle. Cancer Invest 17(7): 545-6. (1999).

Hryniuk W. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer.  J Natl Cancer Inst 91(16): 1425, 1999.

Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, and Ensley J.  Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 86(11): 2364-9, 1999.

Hussain M, Fisher EI, Petrylak DP, Wood DP, Small EJ, Eisenberger A, Crawford ED:  Androgen deprivation + 4 courses fixed schedule suramin in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.  J Clin Oncol, (in press).

Jaszewski R, Khan A, Sarkar FH, Kucuk O, Tobi M, Zagnoon A, Dhar R, Kinzie J, and Majumdar AP. Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines.  Am J Physiol 277(6 Pt 1): C1142-8, 1999.

Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR, and Lucas DR.  Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.  Cancer 86(6): 976-81, 1999.

Kalemkerian GP, Belzer K, Wozniak AJ, Gaspar LE, Valdivieso M, and Kraut MJ. Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer. Lung Cancer 25(3): 175-82, 1999.

Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, and Appelbaum FR.  A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.  Leuk Res 23(9): 787-94, 1999.

Kish JA, Benedetti JK, Balcerzak SP, Veith RW, Davis R, Pollock TW, Schuller DE,  and Ensley JF. Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group Study. Cancer J Sci Am 5(5): 307-11, 1999.

Klein J, Maroto Rey P, Dansey R., Karanes C, Du W, Abella E, Cassells L, Hamm C, Peters W, and Baynes R.  Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Bone Marrow Transplantation: (in press).

Klein J, Rey P, Dansey R, Karanes C, Abella E, Cassells L, Hamm C, Flowers M, Couwlier C, Peters W, and Baynes R.  Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells.  Bone Marrow Transplant 24(9): 959-63, 1999.

Kosinski D, Grubb BP, Lachant NA.  Erythropoietin as therapy for severe refractory orthostatic hypotension associated with pure autonomic failure.  J Isr Heart Soc, 9:32-36, 1999.

Kucuk O, Kilton L, Wade J, Houston J, Blough R, Watkins A, Benson A. Menogaril in the treatment of multiple myeloma and chronic lymphocytic leukemia: An Illinois Cancer Center Study. Am J Clin Oncol (in press)

Kucuk O, Pandya KJ, Skeel RT, Hochster H, and Abeloff MD.  Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). Breast Cancer Res Treat 57(2): 201-6, 1999.

Kucuk O, Pandya K, Shevrin D, Bonomi P.  Phase II trial of cisplatin, 5-fluorouracil and etoposide in advanced measurable non-small cell lung cancer: An ECOG pilot Am J Clin Oncol (in press).

Kucuk O, Young M, Habermann T, Wolf B, Jimeno J, Cassileth P. Phase II trial of Didemnin B in previously treated non-HodgkinÕs lymphoma: An Eastern Cooperative Oncology Group (ECOG) Study. Am J Clin Oncol (in press).

Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, and Schiffer CA.  Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.  J Clin Oncol 17(9): 2831, 1999.

Li Y, Bhuiyan M, Vaitkevicius VK, and Sarkar FH.  Structural alteration of p53 protein correlated to survival in patients with pancreatic adenocarcinoma.  Pancreas 18(1): 104-10, 1999.

Liang JY, Fontana JA, Rao JN, Ordonez JV, Dawson MI, Shroot B, Wilber JF, and Feng P.  Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate 38(3): 228-36, 1999.

Liu KZ, Schultz CP, Johnston JB, Beck FW, Al-Katib AM, Mohammad RM, and Mantsch HH.  Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line.  Leukemia 13(8): 1273-80, 1999.

LoRusso PM, Parchment R, Demchik L, Knight J, Polin L, Dzubow J, Behrens C, Harrison B, Trainor G, and Corbett TH.  Preclinical antitumor activity of XK469 (NSC 656889).  Invest New Drugs 16(4): 287-96, 1999.

Madrid FF, Vande Vord PJ, Ynag X, Karvonen RL, Simpson PM, Kraut MJ, Granda JL, Tomkiel JE. Clinical Cancer Research 5 1393-1400, 1999

Mankoff DA, Shields AF, Link JM, Graham MM, Muzi M, Peterson LM, Eary JF, and. Krohn KA Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies.  J Nucl Med 40(4): 614-24, 1999.

Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, and Sondak VK.  Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.  J Cancer Res Clin Oncol 125(5): 292-6, 1999.

Mohammad RM, Li Y, Mohamed AN, Pettit GR, Adsay V, Vaitkevicius VK, Al-Katib AM, and Sarkar FH. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreas 19(4): 353-61, 1999.

Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FW, Wall NR, and Al-Katib AM. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncol 14(5): 945-50, 1999.

Mohammad RM, Limvarapuss C, Wall NR, Hamdy N, Beck FW, Pettit GR, and Al-Katib A.  A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human WaldenstromÕs macroglobulinemia xenograft model.  Int J Oncol 15(2): 367-72, 1999.

Moore RE, Smith CD, Patterson G, Mooberry ML, Susan L, Corbett TH, Valeriote, FA,Golakoti T.   Title: Cryptophycins   Patent #US5952298   File Date 6/7/1995 Issued Date 9/14/1999.

Moore RE, Smith CD, Patterson G, Mooberry ML, Susan L, Corbett TH, Valeriote FA, Golakoti T.   Title: Cryptophycins   Patent #US5955423   File Date 6/7/1995 Issued Date 9/21/1999.

Moore RE, Tius MA, Barrow RA, Liang J, Corbett TH, Valeriote FA, Golakoti T, and Hemscheidt, TK.  Cryptophycins from Synthesis Patent #US6013626 issued 1/11/2000.

Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, and Gandara D.  Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.  J Clin Oncol 17(8): 2300-8, 1999.

Negrin R, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu W, Johnston L, Shizuru J, Stockert-Goldstein K, Blume K, Weissman I, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J.   Transplantation of Highly Purified CD34+Thy-1+Hematopoietic Stem Cells in Patients with Metastatic Breast Cancer.

O’Byrne KJ, Philip PA, Propper DJ, Braybrooke JP, Saunders MP, Bates NP, Taylor MA, Madigan D, S. Ganesan T, Talbot DC, and Harris AL.  A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.  Ann Oncol 10(8): 981-3, 1999.

Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, WatanabeY, Pass HI.  VEGF and VEGF Type C Play An Important Role in Angiogenesisand Lymphangiogenesis in Human Malignant Mesothelioma. Br J.Cancer, September 1999; 81 (1): 54-61.

Parchment R, Pessina A.  Haematotoxicity in Vitro (ATLA) (in press), 1999.

Parchment R.  Hematotoxicology In Vitro (ATLA) (in press), 1999.

Pauley RJ, Santner SJ, Tait LR,. Bright RK, and Santen RJ.  Regulation of CYP19 Aromatase in Breast Stromal Fibroblasts.  J Clin Endo & Metab 85(2): (in press).

Pernick NL, Biernat L, Du W, Visscher DW.  Clinicopathologic Analysis of Fas, Fas Ligand and other Biomarkers in Locally Advanced BreastCarcinoma. Breast Journal (in press).

Pessina A, Albella B, Bueren J, Brantom P, Casati S, Corrao G, Gribaldo L, Parchment R, Parent-Massin D, Piccirolo M, Rio B, Sacchi S, Schoeters G, Van den Heuvel R.  Method Development For a Prevalidation Study of In Vitro GM-CFU Assay for Predicting Myelotoxicity.  (ATLA) (in press), 1999.

Philip PA, Ali-Sadat S, Doehmer J, Kocarek T, Akhtar A, Lu H, and Chan KK.  Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemother Pharmacol 43(1): 59-67, 1999.

Philip PA, Ibrahim D, Zalupski M, Arlauskas P, and Shields A.  Gemcitabine and UFT plus oral calcium folinate: phase I study.  Oncology (Huntingt) 13(7 Suppl 3): 116-9, 1999.

Philip PA, Rea D, Mitchell K, Carmichael J, Harris AL, and Talbot DC.  A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.  Clin Oncol 11(2): 84-9, 1999.

Prapurna-Danam RP, Lu MH, Lewis SM, Djuric Z, Tang N, and Hart RW.  The effect of dietary fat on malondialdehyde concentrations in Fischer 344 rats. Mech Ageing Dev 110(1-2): 87-99, 1999.

Prasad AS, Beck FW, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT, and Swerdlow P.  Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am J Hematol 61(3): 194-202, 1999.

Qiu YL, Hempel A, Camerman N, Camerman A, Geiser F, Ptak RG, Breitenbach  JM, Kira T, Li L, Gullen E, Cheng YC, Drach JC, and Zemlicka J.  Methylenecyclopropane analogues of nucleosides: synthesis, absolute configuration, and enantioselectivity of antiviral effect of (R)-(-)- and (S)-(+)-synadenol.  Nucleosides Nucleotides 18(4-5): 597-8, 1999.

Qiu YL, Ptak RG, Breitenbach JM, Lin JS, Cheng YC, Drach JC, Kern ER, and Zemlicka J.  Synthesis and antiviral activity of phosphoralaninate derivatives of methylenecyclopropane analogues of nucleosides. Antiviral Res 43(1): 37-53, 1999.

Qiu YL, and Zemlicka J.  Synthesis of new nucleoside analogues comprising a geminal difluorocyclopropane moiety as potential antiviral/antitumor agents.  Nucleosides Nucleotides 18(10): 2285-300, 1999.

Qiu YL, Ksebati MB, Zemlicka J.   Synthesis of (Z)- and (E)-9-[(-2-hydroxyethylidene)cyclopropyl]-adenine Ð new methylenecyclopropane analogues of adenosine and their substrate activity for adenosine deaminase.  Nucleosides & Nucleotides, (in press).

Rengen R, Ochs HD, Sweet MI, Keil M, Gunning WT, Boxer L, Lachant NA, Omann GM.  Mutation or absence of WASP in patient hematopoietic cells spares cytoskeletal function but increases caspase-3 activity resulting in accelerated apoptosis.  Blood, (in press).

Rishi AK, Sun RJ, Gao Y, Hsu CK, Gerald TM, Sheikh MS, Dawson MI, Reichert U, Shroot B, AJ Jr, Brewer G, and Fontana JA.  Post-transcriptional regulation of the DNA damage-inducible gadd45 gene in human breast carcinoma cells exposed to a novel retinoid CD437.  Nucleic Acids Res 27(15): 3111-9, 1999.

Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, and Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.  J Clin Oncol 17(10): 3064-74, 1999.

Rosen  PJ, Rankin C, Head DR,  Boldt DH, Luthardt  Ph.D, Norwood T, Pugh RP, Karanes C, Appelbaum FR.  A Phase II Study of High Dose ARA-C and Mitoxantrone for Treatment of Relapsed or Refractory Adult Acute Lymphoblastic Leukemia:  A Southwest Oncology Group Study,  Leukemia Research,  August 1999, (in press).

Runge-Morris M, Wu W, and. Kocarek TA.  Regulation of rat hepatic hydroxysteroid sulfotransferase (SULT2-40/41) gene expression by glucocorticoids: evidence for a dual mechanism of transcriptional control.  Mol Pharmacol 56(6): 1198-206, 1999.

Rybak RJ, Hartline CB, Qiu YL,  Zemlicka J, Harden E, Marshall G, Sommadossi JP,  Kern ER .  In vitro activity of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus infections. Antimicrob Agents &  Chemother, (in press).

Rybak RJ, Zemlicka J, Qiu YL, Hartline CB, and Kern ER.  Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides.  Antiviral Res 43(3): 175-88, 1999.

Samlowski W, Lew D, Keubler PJ, Kolodiej MA, Medina JE, Mangan KF, Moore Jr. DF, Schuller DE, Ensley JE. Evaluation of tolmudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.  A Southwest Oncology Group Study. Investigational New Drugs, 16:271-274, 1999.

Schiffer CA.  Granulocyte transfusion therapy. Curr Opin Hematol 6(1): 3-7, 1999.

Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM.  A double blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjuct to induction and consolidation therapy for patients with acute myeloid leukemia.  Blood, 1999 (in press).

Shao ZM, Li J, Wu J, Han QX, Shen ZZ, Fontana JA, and Barsky SH.  Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis.  Breast Cancer Res Treat 53(3): 263-9, 1999.

Shibuya TY, Wei WZ, Zormeier M, Ensley J, Sakr W, Mathog RH, Meleca RJ, Yoo G, June CH, Levine B, and Lum LG.  Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 125(11): 1229-34, 1999.

Shibuya TY, Wei WZ, Zormeier M, Ensley J, Sakr W, Mathog R, Meleca RJ, Yoo G, June CH, Levine B and Lum LG. Anti-CD3/anti-CD28 bead overcomes T cell unresponsiveness in HNSCC patients. Archives of Otolaryngology-Head and Neck Surgery, (in press).

Shields AF, Philip PA, LoRusso PM, Ferris AM, and Zalupski MM.  Phase II study of CI-958 in colorectal cancer. Cancer Chemother Pharmacol 43(2): 162-4, 1999.

Shih C, Gossett LS, Gruber JM, Grossman CS, Andis SL, Schultz RM, Worzalla JF, Corbett TH, and Metz JT.  Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region.  Bioorg Med Chem Lett 9(1): 69-74, 1999.

Shillitoe EJ, May M, Patel V, Lethanakul C, Ensley JF, Strausberg RL, Gutkind JS. Genome-wide analysis of oral cancer - Early results from the Cancer Genome Anatomy Project. Oral Oncology, (in press).

Simon MS, Brown DR, Du W, LoRusso P, and Kellogg CM.  Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit. Am J Clin Oncol 22(1): 42-6, 1999.

Simon MS, Djuric Z, Stephens D, Heilbrun LK.  Recruitment for a pilot case control study of oxidation DNA damage and breast cancer risk. Amer. J. Clin. Oncol., (in press).

Simon MS, Heilbrun LK, Stephens D, Lababidi S, Djuric Z.  An evaluation of  oxidative DNA damage and the risk of breast cancer: a pilot case-control study.   Accepted by American J. of Clinical Oncology, 8/99.

Simpson NE, and Evelhoch JL.  Deuterium NMR tissue perfusion measurements using the tracer uptake approach: II. Comparison with microspheres in tumors.  Magn Reson Med 42(2): 240-7, 1999.

Simpson NE, He Z, and Evelhoch JL.  Deuterium NMR tissue perfusion measurements using the tracer uptake approach: I. Optimization of methods.  Magn Reson Med 42(1): 42-52. 1999.

Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, Taylor SA, Balcerzak SP, and Meyskens Jr  FL. A phase II evaluation of all-trans-retinoic acid plus interferon alfa- 2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am 5(1): 41-7. (1999).

Steele GD, Herndon JE, Bleday R, Russell A, Benson A, Hussain M, Burgess A, Tepper JE, Mayer RJ: Sphincter sparing treatment for distal rectal adenocarcinoma.  Annals of Surgical Oncol 6:5433-441, 1999.

Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, and Mayr N.  MR imaging of tumor microcirculation: promise for the new millenium. J Magn Reson Imaging 10(6): 903-7, (1999).

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, and Weisskoff RM.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)- weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3): 223-32, 1999.

Tomaszewski JE, Parchment RE.  In Vitro Guidance for Drug Development. J. Toxicological Sciences, (in press), 1999.

Uchida H, Kodama EN, Yoshimura K, Maeda Y, Kosalaraksa P, Maroun V, Qiu YL, Zemlicka J, and Mitsuya H. In vitro anti-human immunodeficiency virus activities of Z- and E- methylenecyclopropane nucleoside analogues and their phosphoro-L- alaninate diesters. Antimicrob Agents Chemother 43(6): 1487-90, 1999.

Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes-An Overview of the Pharmacokinetics and Pharmacodynamics. Seminars in Oncology, (in press) 1999.

Vaishampayan U, Parchment RE, Jasti BR, and Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54(6A Suppl): 22-9, 1999.

Varie DL, Shih C, Hay DA, Andis SL, Corbett TH, Gossett LS, Janisse SKMartinelli, MJ, Moher ED, Schultz RM, and Toth JE. Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).  Bioorg Med Chem Lett 9(3): 369-74, 1999.

Varterasian M, Al-Katib A. Epidemiology of Lymphoma inDetroit, (in press) 1999.

Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Eilender DS, Murgo A, Wall N, Al-Katib A. Phase II trial of bryostatin 1 in patients with relapsed low grade non-HodgkinÕs lymphoma and chronic lymphocytic leukemia.  Clinical Cancer Research, (in press).

Wall NR, Mohammad RM, and Al-Katib AM.  Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.  Leuk Res 23(10): 881-8, 1999.

Wall NR, Mohammad RM, Nabha SM, Pettit GR, and Al-Katib AM.  Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.  Biochem Biophys Res Commun 266(1): 76-80, 1999.

Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, and Jones RF.  Protection against mammary tumor growth by vaccination with full- length, modified human ErbB-2 DNA.  Int J Cancer 81(5): 748-54, 1999.

Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, and Bloomfield CD.  Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 93(11): 3983-93, 1999.

Wood GW, Hausmann EH, and Kanakaraj K.  Expression and Regulation of Chemokine Genes in the Mouse Uterus During Pregnancy.  Cytokine 11(12): 1038-1045, 1999.

Wood GW, Turner T, Wang YY, and Holladay FP  Immune rejection of intracerebral gliomas using lymphocytes from glioma- bearing rats. J Immunother 22(6): 497-505, 1999.

Wu J, Shen ZZ, Lu JS, Jiang M, Han QX, Fontana JA, Barsky SH, and Shao ZM.  Prognostic role of p27Kip1 and apoptosis in human breast cancer.  Br J Cancer 79(9-10): 1572-8, 1999.

Yoo JY, Wang XW, Rishi AK, Gustafson TA, and Hamburger AW.  Identification of a new ERB3 interacting protein EBP1 that translocates into the nucleus after heregulin stimulation. British J. Cancer (in press).

Yoo GH, Hocwald E, Korkmaz H, Du W, Logani S, Kelley JK, Sakr W, Jacobs JR.  Assessment of Carotid Artery Invasion in Patients with Head and Neck Cancer, Laryngoscope (in press).

Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, and Mitsuya H.  In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.  Antimicrob Agents Chemother 43(10): 2479-83, 1999.

Yu F, and Djuric Z.  Analysis of 5-hydroxy-2Õ-deoxycytidine and 5-hudroxymethyl-2Õ-deoxyuridine by GC/MS.  Biomarkers 4: 85-92. (1999).

Zhang XM, Lin H, Chen C, and Chen BD.  Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells.  Biochem J 340(Pt 1): 127-33, 1999.

Zhang Y, Huang Y, Rishi AK, Sheikh MS, Shroot B, Reichert U, Dawson M, Poirer G, and Fontana JA. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid.  Exp Cell Res 247(1): 233-40, 1999.

Zhang Y, Rishi AK, Dawson MI, Tschang R, Farhana L, Boyanapalli M, Reichert U, Shroot B, Van Buren EC, and Fontana JA. Inhibition of S phase arrest and apoptosis induced in normal mammary epithelial cells by a novel retinoid. Cancer Research (in press).

Zheng GG, Wu KF, Geng YQ, Kong J, Al-Katib A, Dan M, and Chen B.  Expression of membrane-associated macrophage colony-stimulating factor (M-CSF) in HodgkinÕs disease and other hematologic malignancies.  Leuk Lymphoma 32(3-4): 339-44, 1999.

Books, Chapters and Reviews

Baynes R. Alcohol and Hemochromatosis. Hemachromatosis. B. J. a. E. CQ: (in press).

Baynes R. The serum transferrin receptor and iron status. Trace Elements in Man and Animals. 9: (In press)

Baynes R, Dansey R, Klein J, Karanes C, Abella E, Cassells L, Wei W, Galy A, Wood G and Peters W. High dose chemotherapy and peripheral blood progenitor cell transplantation in patients with breast cancer.: (in press).

Baynes R, and Peters W. High dose chemotherapy and stem cell transplantation for breast cancer. Karmanos Cancer Institute High-dose Newsletter 1: 1-9, 1999.

Depper JB, Poore KM, Uhley VE, Maranci V, Lababidi S, Heilbrun L, Djuric Z.  Women are able to consume eleven servings of fruits and vegetables daily with or without lowering fat intake.  Presented to the American Institute for Cancer Research (AICR), Washington DC, September 1999.

Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, Swartz HM. Applications of Magnetic Resonance in Model Systems: Cancer Therapeutics.  Neoplasia (in press).

Fontana JA, and Rishi AK. Retinoid receptors and cancer. Cancer Chemotherapy and Biotherapy: Principles and Practice. Editor: Bruce A. Chabner (in press).

George V, Hussain M.:  Is Early Hormonal Therapy Preferrable.  In Advanced Therapy of Prostatic Disease.  M Resnick & I. Thompson (eds.).  B.C. Decker Inc., Hamilton, Canada,  (in press), 1999.

Gillies RJ, Bhujwalla ZM, Evelhoch JL, Garwood M, Neeman M, Robinson SP, Sotak CH, and van der Sanden B.  Applications of Magnetic Resonance in Model Systems: Tumor Biology and Physiology.  Neoplasia (in press)

Hussain M, Petrylak D, Fisher E, Tangen C, and Crawford D.  Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.  Semin Oncol 26(5 Suppl 17): 55-60, 1999.

Karanes C, Lachant NA.. The Acute Leukemias.  In Skeel RT (ed). Handbook of Cancer Chemotherapy (5th Edition). pp. 405-447, 1999.

Klein J, Peters W, and Baynes R. High-dose chemotherapy and hematopoietic stem cell transplantation for ovarian cancer. Gynecologic oncology - principles and practice of chemotherapy. D. G. a. B. V. V, Arnold London: 127-145, 1999.

Kurnik R, Jona J, and Jasti BR.  Application of Neural Networks to Optimize Flux Profiles for Transdermal Systems.   In: Intelligent Materials & Novel Concepts for Controlled Release Technologies (eds Dinh, DeNuzzio, and Comfort), ACS B Symposium Series 728.  205-218, 1999.

Lachant NA.  Nonimmune Hemolytic Anemia.  In Rakel RE, Bope ET (eds).  Conn’s Current Therapy 2001 (53rd edn).  (in press).

Larson RA, Dodge RK, Bloomfield CB, Schiffer CA.  Treatment of biologically determined subgroups of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B studies.  In: Acute Leukemias: Prognostic Factors and Treatment Strategies. Hiddemann W., Buchner T, Wormann P (eds.), Springer-Verlag, Berlin, Heidelberg (in press).

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensified post remission chemotherapy for adults with AML: An update of CALGB 8525.  In: Acute Leukemias: Prognostic Factors and Treatment Strategies. Hiddemann W., Buchner T, Wormann P (eds.), Springer-Verlag, Berlin, Heidelberg (in press).

Minev BR, Chavez FL  and Mitchell MS. Cancer vaccines: novel approaches and new promise. Pharmacol Ther 81(2): 121-39, 1999.

Mitchell MS. Biologic agents approved for use, Ibid: (in press).

Mitchell MS, and Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 26(4 Suppl 12): 108-16, (1999).

Mohammad RM, Beck FWJ, Wall N, Al-Katib A. Human Cell Culture, B-Cell Lines. University College London, (in press)  1999.

Mohammad RM, Beck FWJ, Wall N, Al-Katib A. Human Cell Culture, Non-Hodgkin’s Lymphoma B-Cell Lines. University College London, (in press), 1999.

Peters W, and Baynes R.  Autologous hematopoietic cell transplantation for breast cancer. Hematopoietic Cell Transplantation. E, Thomas B. KG and S. Forman. Oxford, Blackwell Scientific Publications: 1029-1042, (1999).

Peters W, Dansey R, Klein J, and Baynes R.  High dose chemotherapy and peripheral blood progenitor cell transplantation in patients with breast cancer. The Oncologist: (in press).

Peters W, Hamm C. and Baynes R.  Autologous hematopoietic stem cell transplantation. Cancer Medicine: (in press).

Redman BG, Flaherty LE.  Chemotherapy of Melanoma of the Female Genital Tract.  In Gynecologic Cancer:  Principles and Practice of Chemotherapy, G.Deppe, V.Baker (eds.), Lippincott-Raven, Philadelphia, 1999.

Sadar MD, Hussain M, Bruchovsky N.: Prostate cancer: Molecular biology of early progression to androgen independence.  Endocrine Related Cancer, 6:1-16, 1999.

Sakr WA Land SJ, Akroush AM., Sarkar FH, Haas GP, Heilbrun LK, Everson RB.  Determination of Steroid Hormone Receptor Polymorphisms in Prostate Tissue from Autopsy.   Presented to the United States and Canadian Academy of Pathology (USCAP), San Francisco, CA, March 1999.

Sarkodee-Adoo C, Schiffer CA.  Acute myeloid leukemia.  In: Current Therapy in Cancer, Vol 2.  Foley J, Vose JM, Armitage JO eds.  WB Saunders. (in press).

Schiffer CA.  A perspective on cytokine use.  In: Diagnosis and Treatment of Radiation Injury. (in press).

Schiffer CA.  Platelet transfusion: future considerations..  In: Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity. Kickler TC and Herman JH eds. Amer Assoc of Blood Banks pp 287-98, 1999.

Schiffer CA, Stone R, Peterson B, Moore J for the CALGB.  Cancer and Leukemia Group B Studies With Hematopoietic Growth Factors in Patients with Acute Myeloid Leukemia. In: Acute Leukemias: Prognostic Factors and Treatment Strategies. Hiddemann W., Buchner T, Wormann P (eds.), Springer-Verlag, Berlin, Heidelberg (in press).

Schiffer CA.  The challenge of alloimmunization to platelet transfusion.  In: Acute Leukemias: Prognostic Factors and Treatment Strategies. Hiddemann W., Buchner T, Wormann P (eds.), Springer-Verlag, Berlin, Heidelberg (in press).

Shields AF, Ho PT and Grierson JR  The role of imaging in the development of oncologic agents. J Clin Pharmacol Suppl: 40S-44S, 1999.

Tiguert R, Forman JD, Hussain M and Wood Jr D P. Radiation therapy for a rising PSA level after radical prostatectomy. Semin Urol Oncol 17(3): 141-7, 1999

Vaishampayan U, Hussain M.: Adjuvant chemohormonal trials for locally advanced prostate cancer. Current Oncology Reports, (in press) 1999.

Yue W, Mor G, Naftolin F, Pauley R, Shim W-S, Harvey H, and Santen RJ.  Use of Aromatase Inhibitors in Breast Carcinoma.  In:  Endocrine Management of Breast Cancer.  J Robertson, R Nicholson and D Hayes (ed), (in press).

Zemlicka J.   Enantioselectivity of the antiviral effects of nucleoside analogues.  Pharmacol Ther, (in press).

Zonder J, and Philip PA.  Bryostatin 1. Expert Opinion on Investigational Drugs 8(12): 2189-2199, 1999.

Abstracts, Letters to the Editor and Articles in Non-Refereed Journals

Abella E, Karanes C,  Klein J, Dansey R, Kukuruga D, Nadeau T, Cassells L,  Peters W, Baynes R. Superior results following matched unrelated donor (MUD) bone marrow transplant (BMT) in severe aplastic anemia (AA) patients using a non-TBI containing preparative regimen.  (Accepted ABMTR/ASBMT conference 1999).

Abella E, Karanes C, Klein J, Dansey R, Kukaruga D,  Cassells L, Peters W, Baynes R.  Matched Unrelated Donor (MUD) Bone Marrow Transplants (BMT) in Severe Aplastic Anemia (AA) Patients Using a Non-TBI Containing Preparative.  American Society of Hematology, (Blood) 94: 4972 1999.

Abella E, KuKuruga D, Du W, Mohamed A, Bakdounes K, Nadeau T, Karanes C, Klein J, Dansey R, Cassells L, Peters W and Baynes R.  Clinical comparison of variable number tandem repeats (VNTR), cytogenetics , and fluorescence in situ hybridization (FISH) in allogeneic stem cell transplant patients.  (ABMTR/ASBMT 1999).

Abraham OC, Klein J, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R, Chandrasekar PH. *Infectious Complications in Women Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation  (PBPCT) for Breast Cancer.

Al-Sarraf M, LeBlanc M, Giri PGS, Fu K, Cooper J, Young T, Forastiere       A, Adams G, Sakr W, Schuller D, Ensley J. Superiority of chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients with advanced nasopharyngeal cancer (NPC) Intergroup 0099 (SWOG 8892), RTOG 8817, ECOG 2388) phase III study. Progress report. 9th International Congress on Anti-Cancer TreatmentAbs 034. Paris, France, February 2-5, 1999.

Andersen JC, Haggood AS*, Boxwala I*.  Amegakaryocytic Thrombocytopenia in a Hypogammaglobulinemic Man Responsive to Repetitive Intravenous Immunoglobulin Administration.  Blood, Vol. 94 #10 (supp.1, p. 172b), Abstract #3945, November 15, 1999.

Aref A, Berkey BA, Schwasw JG, Ensley JF, Schuller DE, Haselow RE, Ervin TJ, Laramore GE. The influence of beam energy on the outcome of post operative radiotherpy in head and neck cancer patients: Secondary analysis of RTOG 85-03. ASTRO, 1999.

Arias-Mendoza F, Brown TR, Charles HC, Zakian K, Schwarz A, Doyle VL, Nelson SJ, Rijpkemo M, Glickson JD, Evelhoch, JL.  Methodological Standardization for a Multi-institutional in Vivo Trial of Localized 31P MR Spectroscopy in Human Cancer Research.   7th Mtg Int Soc Magn Reson Med, Philadelphia, PA, May 1999.

Bacs— Zs, Land, SJ,  Klein, J, States, JC, Everson, RB, and Eliason, JF.  Quantitative methods for examining the drug resistence phenotype of micrometastatic cancer cells in bone marrow:  expression of resistance-related proteins.  AACR Annual Meeting, April 10-14, 1999, Philadelphia, PA.

Baer MR, George SL, Dodge RK, Cooke K, Caligiuri MA, Powell BL, Kolitz JE, Schiffer CA, Larson RA.  Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) >60 years (CALGB 9720).  Blood 94:1704, 1999.

Baynes RD, Wood GW, Dansey RD, Klein JL, Cassells L, Karanes C, Abella E, Peters WP.  Combined modality high dose chemotherapy and adoptive immunotherapy for chemoresistant metastatic breast cancer.  Second international conference on interleukin-2, 1999.

Ben-Joseph E, Han S, Mertens W, Porter AT, Filipczak L, Prokop S, Hussain M:  Neoadjuvant estramustine/etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer. Proc Am Soc Clin Oncol 18, #   , 1999.

Caligiuri MA, Lee EJ, Baer MR, Dodge R, Cooke K, Szatrowski T, Schiffer CA, Bloomfield CD, Larson RA.  Daily low dose interleukin 2 (IL02) therapy with or without intermediate dose pulsing in acute myeloid leukemia (AML) patients (PTS) > 60 years old in first complete remission (CR1):  A feasibility study (CALGB 9420).  Blood 94:331, 1999.

Cassells L, Dansey RD, Karanes C, Klein JL, Abella E, Peters WP, Baynes RD.  Outcome of matched unrelated donor (MUD) transplants in selected patients older than fifty years of age.  Proc  Am Soc Clin Oncol, 18, 437a, 1999.

Chen C, and Chen B.  Bryostatin 1 induced XIAP mRNA expression in apoptosis resistant THP-1 cells.  Proc. 1999 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.  Clin. Cancer Res. Volume 5, 3793s, 1999.

Chilukuri S,  Alangarden  G,  Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, Chandrasekarr PH.  Antifungal Chemoprophylaxis  in Bone Marrow/Stem Cell Transplantation:  An International Survey.   Annual Meeting of the Infectious Disease Society of America, June 1999.

Corbett TH, Panchapor C, Polin L, Lowichik N, Pugh S, White K,Kushner J, Meyer J, Czarnecki J, Chinnukroh S, Edelstein M, LoRusso P,  Horwitz JP, Grieshaber C, Perni R, Wentland M, Coughlin S, Elenbaas S, Philion R, and Rake J.  Preclinical Antitumor Activity of Thioxanthone SR271425.   AACR Abst-2624, 40:396, 1999.

Dansey R,  Abella E,  Karanes C, Klein J, Cassells L, Peters W, Baynes R.  Favorable results of matched unrelated donor  (MUD) transplants in selected patients older than fifty years of age.  ABMTR/ASBMT conference 1999.

Dansey R, Abella E, Karanes C, Klein J, Cassells L, Peters W, Baynes R. Outcome of matched unrelated donor (MUD) transplants in selected patients older than fifty years of age. (ABMTR/ASBMT 1999).

Dansey R, Rey DM,  Peters W, Karanes C,  Klein J,  Cassells L,  Abella S, Baynes R.  Autologous transplantation for relapsed/refractory HodgkinÕs disease using Cyclophosphamide, Platinum and BCNU, (ASCO 1999).

Dansey R, Karanes C, Abella S, Klein J, Cassells L, Peters W, Baynes R.  Unrelated Donor Transplants in Patients over the Age of 45 Years.  ABMTR/IBMTR Tandem BMT Meetings, Keystone, Colorado, March 1999.

Dansey R, Klein J, Karanes C, Hamm C, Cassells L, Abella E, Gadgeel S, Peters W, Baynes R.  BCNU Cyclophosphamide Cisplatin (Stamp I) With Autologous Stem Cell Rescue for HodgkinÕs Disease.  American Society of Hematology, (Blood)  94: 5010, 1999.

Dansey R, Zielinsky I, Klein J, Karanes C, Abella S, Carriion R, Du W, Cassells L, Peters W, Baynes R.  Optimization of Peripheral Blood Stem Cell Collections Using Peripheral Blood CD 34 Levels and Routine High Volume Leukopheresis.  Accepted ABMTR/IBMTR Tandem BMT Meetings, Keystone, Colorado, March 1999.

Djuric Z, Sarkar F, Redd JN and Kucuk O.  Effect of soy isoflavone dietary supplementation on levels of oxidative DNA damage in blood of women.  The Toxicologist, 48 (no. 1-S):204, 1999.

Djuric Z, and Strasburg GM.  Effect of buffer on DNA and lipid oxidation,  Proc. Amer. Assoc. Cancer Res., 40:645, 1999.

Djuric Z, Chen G, Mekhovich O, Sarkar F, Tainsky M, and Kucuk O.  Effect of soy isoflavone dietary supplementation on levels of oxidative stress, International Symposium on the Health Effects of Soy, Washington, D.C. October 1999.

Djuric Z, Chen G, Mekhovich O, Depper JB, Poore KM, Redd JN, Maranic V, Lababidi S, and Heilbrun LK  Dietary intervention in women at increased risk for breast cancer, Keystone Symposia, (in press).

Djuric Z.  Fat, calories and oxidative DNA damage, Proc. Amer. Assoc. Cancer Res., (in press).

Ferlazzo G, Klein J, Paliard X., Wei Wei-Zen, Galy A.  Dendritic cells generated from CD34+ progenitor cells with flt3-ligand, c-kt-ligand, GM-CSF, TNF-( and IL-4 are functional antigen-presenting cells resembling mature monocyte-derived DC. 1999  Journal of Immunotherapy, (in press).

Flaherty LE, Atkin M, Sosman J, Clark J, Margolin K, Dutcher J, Gordon M, and Weiss G.  Randomized Phase II Trial of Chemotherapy and Outpatient biotherapy with Interleukin-2 (IL-2) and Interferon Alpha (IFN) in Metastatic Malignant Melanoma (MMM) Proc Ð ASCO Vol. 18 453a (Abstract 2070), 1999.

Grierson JR, Shields AF. Optimizing labeling substrate structure for 3Õ-deoxy-3Õ-[F-18]fluorothymidine:  [F-18]FLT.  Annual Meeting of the Society of Nuclear Medicine Convention, Los Angeles, June, 1999.

Hussain M, Fisher E, Forman J, Sakr W, Drelichman A, Akhter S, Grossman HB, Crawford ED:  Phase II evaluation of cisplatin + 5-FU + radiation therapy in patients with locally advanced/inoperable bladder cancer. A Southwest Oncology Group Study 9312.  Proc Am Soc Clin Oncol 18, # 1281, 1999.

Kaur J, Singh P, Lachant N.  Drug-induced Pancytopenia. Presented at meeting of Michigan Chapter ACP, September, 1999.  Proceedings Michigan ACP, 1999.

Kirkwood JM, Ibrahim J, Sondak V, Ernstoff M, Flaherty LE, Smith T, Richards J, Rao U, Steele M, Blum R.  Preliminary Analysis of the E 1690/S9111/C9190 Intergroup Rostoperative Adjuvant Trial of High and Low Dose Interferon Alpha 2B (HDI and LDI) in High Risk Primary of Lymph Node Metastatic Melanoma. Proc. ASCO Vol. 18 537a (Abstract 2072), 1999.

Klein J, Dansey D, Karanes C, Abella E, Cassells L, Hamm C, Peters W, Baynes R.  Stamp I HDC and CD34 Selected PBPC Transplant for Metastatic Breast; Mobilization, Engraftment and Safety.  American Society of Hematology, (Blood) 94: 1570, 1999.

Klein JL, Dansey R, Karanes C, Hamm C, Cassells L, Peters WP, Baynes RD.  High-dose Chemotherapy (HDC) Stamp I and Peripheral Blood Progenitor Cell Transplantation (PBPCT) Following Adriamycin Induction Chemotehrapy for High-Risk Primary and Locally Advanced Breast Cancer (LABC). Am Soc Clin Oncol 1999.

Kouides PA, Gunning WT, Braggins C, Calomeni EP, Howard F, Lachant NA.  Decreased platelet dense granule number and decreased platelet total dense granule volume associated with menorrhagia. Presented at National Meeting of American Society of Hematology, New Orleans, LA, December 6, 1999.  Blood 94:450a, 1999.

Krishnan S, Chenevert T, Evelhoch JL.  Analysis of Dynamic Contrast-Enhanced MRI in Tumors:  Optimization of Acquisition Parameters.  7th Mtg Int.Soc Magn.Reson Med, Philadelphia, PA, May 1999.

Lachant NA, Andersen JC, Londhe M, Haggood A.  Acquired severe Protein S deficiency in women with sticky platelet syndrome during pregnancy:  Predisposition to thrombosis and response to aspirin and heparin.  Presented at National Meeting of American Society of Hematology, New Orleans, LA, December 6, 1999.  Blood 94:452a, 1999.

Land SJ, Bacsó Z, Klein J, Eliason JF, and Everson RB.  Quantitative methods for examining the drug resistance phenotype of micrometastatic cancer cells in bone marrow:  DNA damage in response to in vitro drug treatment.  AACR Annual Meeting, April 10-14, 1999, Philadelphia, PA.

Liu KZ, Schultz CP, Mohammad RM, Al-Katib A, Mantsch HH. Infrared spectroscopy study of bryostatin 1-induced membrane alterations in B-CLL cell line. Leukemia, 13: 1273-1280, 1999.

Mohammad RM, Li Y, Mohamed AN, Pettit GR, Adsy V, Vaitkevicius VK, Al-Katib A, Sarkar FH Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreases , 19: 353-361, 1999.

Mohammad RM,  Limvarapuss C, Hamdy N, Dutcher BS, Beck FWJ, Wall N, Al-Katib A. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncology, 14:945-950, 1999.

Mohammad RM, Limvarapuss C, Wall N, Hamdy N, Hannoudi G, Mehra V, Pettit GR, Al-Katib A.  A  new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human waldenstrom macroglobulinemia xenograft model. Int J Oncology, 15:367-372, 1999.

Morrison VA, Rai KR, Peterson BL, Kilitz JE, Elias L, Hines JD, Shepherd L, Larson RA, Schiffer CA.  CALGB, SWOG, ECOG, NCIC/CTG.  Transformation to RichterÕÕ syndrome or prolymphocytic leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL):  An Intergroup study (CALGB 9011).  Blood 94:2410, 1999.

Nemeth J, Trivedi C, Barroso U, Upadhya J, Shekarriz B, Polin L, Hussain M, Cher M:  Dose-Intense paclitaxel in prostate cancer: preclinical and clinical feasibility and anti-tumor activity.   AUA 1999.

O’Shaughnessy J, Flaherty LE, Fiorica J, Grove W.   Phase II Trial of CI-994 in Patients (PTS) with Metastatic Renal Cell Cancer Ð Proc.ASCO Vol 18: 349a (Abstract 1346) 1999.

Parchment RE, Jasti BR, Kocarek TA, Wiegand RA, Kassab J, Wurster W, Keyes KA, Grieshaber CK, and LoRusso PM.  Pharmacologic Issues for Fenretinide Chemotherapy (4HPR, NSC-374551). Div of Hematology-Oncology, Karmanos Cancer Institute, Detroit, MI 48201 USA  AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 16- 19, 1999.

Philip PA, Zalupski M. Vaitkevicius VK, Arlauskas P, Shields A. Phase Ii Study of Gemzar and Cisplatin in Advanced Pancreatic Cancer.  Annual Meeting of the American Society for Clinical Oncology, April, 1999.

Poondru S, Purohit V, Parchment RE, Baynes RD, Grieshaber CK, and Jasti BR,  New HPLC Method Using UV Detector for the Estimation of Treosulfan in Biological Samples.  Karmanos Cancer Institute and Dept. of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48201. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 16- 19, 1999.

Poondru S, Phurohit V, Parchment R, Corbett T, Grieshaber C, and Jasti B. Estimation of Treosulfan by High Performance Liquid Chromatography Using UV Detector. AAPS Annual Meeting and Exposition, November 14-18, 1999.

Rishi AK, Hussain A, Zhang YX, Tschang SHR, Sun RJ, Hsu CKA, Sheikh MS, Fontana JA.  Okadaic acid upregulates c-fos gene in estrogen receptor-negative breast carcinoma cells, in part, via 3Õ untranslated region of c-fos gene. Proceedings of American Association for Cancer Research, 40: 367, 1999.

Runge-Morris M and Kocarek TA (1999) Transcriptional regulation of the rat hydroxysteroid sulfotransferase (SULT2-40/41) gene by glucocorticoids. The Toxicologist, 48(1-S): 165, abstr. 777.

Runge-Morris M, Varterasian M, Eilender D, Pemberton P and Al-Katib A. (1999) Mitoxantrone, bleomycin, and methotrexate [MBM] in patients with HIV-associated non-HodgkinÕs lymphoma [HIV-NHL]. Blood 94 (10), Supplement 1: 267b (abstr. 4405).

Samson C, Soulen RL, Shields A, Evelhoch JL, Pipe JG, Latif Z, Morton P. PET and MRI Assessment of Neoadjuvant Therapy for Pancreatic Cancer. Annual Meeting of the AUR, San Diego, CA, March 1999.

Schiffer, CA. Leukemia.  Curr Opin Oncol 11(1): 1-2. 1999

Shields AF, Grierson JR, Muzik O, Stayanoff JC, Lawhorn-Crews JM, Obradovich J, Mangner T. [F-18]FLT imaging and modeling in dogs.  Annual Meeting of the Society of Nuclear Medicine Convention, Los Angeles, June, 1999.

Shields AF, Dohmen BM, Grierson JR, Kuntzsch M, Machulla HJ, Bares R. Imaging with [F-18]FLT and FDG in patients with cancer.  Annual Meeting of the Society of Nuclear Medicine Convention, Los Angeles, June, 1999.

Shields AF, Ahmed S, Zalupski MM, Muzik O, Forman J, Lawhorn-Crews JM, Arlauskas P, Philip PA, Soulen RL, Vaitkevicius VK. FDG-PET evaluation of pancreatic cancer treatment.  Annual Meeting of the Society of Nuclear Medicine Convention, Los Angeles, June, 1999.

Soulen RL, Samson C, Shields A, Evelhoch JL, Pipe JG, Latif Z, Morton PE. MRI and PET Assessment of Neoadjuvant Chemotherapy for Pancreatic Cancer.  7th Mtg Int Soc Magn Reson Med, Philadelphia, PA, May 1999.

Spees WM, Evelhoch JL, Ackerman JJH.  Intracellular Acidification Increases Thermal Sensitivity for The RIF-1 Tumor in Vivo.  7th Mtg Int Soc Magn Reson Med, Philadelphia, PA, May 1999.

Strowbridge AA, Wall N, Aref A, Mohammad R, Yudelev M, Al-Katib A.  Induction of apoptosis in a chemotherapy resistant intermediate grade non-HodgkinÕs lymphoma cell line after neutron radiation.  Pan-Pacific Lymphoma Conference, Hawaii, 1999.

Strowbridge AA, Wall N, Aref A, Mohammad R, Yudelev M, Al-Katib A.  Neutron radiation induces the modulation of bcl-2 and bax protein resulting in apoptosis in a chemotherapy resistant intermediate grade non-HodgkinÕs lymphoma cell line. ASTRO meeting, 1999.

Swerdlow PS, Stockwell C, Littsay L, Jett A, Henry S, Lachant N, Ortega J, Andersen J. Opioid use in hospitalized patients with sickle cell disease.  Presented at National Meeting of Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.  Proceedings National Sickle Cell Disease Program, 1999.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JHJ, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH.  All-trans retinoic acid in acute promyelocytic leukemia:  Long-term outcome results and prognostic factor analysis from intergroup protocol 0129.  Blood 90:3086, 1999.

Trivedi C, Lachant NA.  Hemorrhage and thrombosis in a patient with factor VII deficiency: A consequence of multiple hemostatic abnormalities.  Blood 94:99b, 1999.

Trivedi C, Nemeth JA, Barroso U, Upadhyay J, Shekarriz B, Poplin E, Cher ML, Hussain M:  High dose weekly paclitaxel (P) in prostate cancer (Pca):  Preclinical and clinical feasibility and anti-tumor activity. Proc AACR,  #3459, 1999.

Vasishampayan U, Smith D, Redman B, Kucuk O, Ensley J, Hussain M. Phase II evaluation of carboplatinum, placlitaxel and gemcytabine in advanced urothelial carcinoma. ASCO, 18:1282,  1999.

Wall NR, Mohammad RM, Al-Katib AM.  Susceptibility of acute lymphoblastic leukemia cells, Reh, to apoptosis:The critical role of the Bax:Bcl-2 ratio. Proceedings of the American Association for Cancer Research, 40:577(#3807) 1999.

Weigand RA, Doyle TD, Grieshaber CK, LoRusso PM, Kassab J, Jasti BR, and Parchment RE.  Normal-phase separation of XK-469 Enantiomers (R: NSC-698215, S:NSC-698216) Applied to Preclinical Pharmacology.  Karmanos Cancer Institute, Wayne State University, Detroit MI 48201 and Product Quality Research, CDER, US FDA, Rockville, MD.  AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 16- 19, 1999.

Whitehead RP, Unger J, Flaherty LE, Eckhardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK.  Phase II Trial of CI-994 in Patients with Disseminated Malignant Melanoma:  A Southwest Oncology Group Study Ð Proc.ASCO Vol. 18 454a (Abstract 2138), 1999.

Williams JA, Kintzel PE, Abella E, Klein, J, Dansey R, Karanes C, Baynes R.  Ethanol toxicity with high- dose etoposide:  A case report in two bone marrow transplant recipients (Accepted ABMTR/ASBMT conference 1999).

Wozniak, A J. Single-agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 26(5 Suppl 16): 62-6; 1999 discussion 71-2.

Zemlicka J, Qiu YL, Kira T, Gullen E, Cheng YC, Ptak RG, Breitenbach JM , Drach JC, Hartline CB, Kern ER.  Enantioselectivity of the antiviral effect of methylenecyclopropane nucleoside analogues.  12th International Conference on Antiviral Research , Jerusalem, Israel, March 21 Ð 25, 1999.  Antiviral Res  41, A14, 1999 abstract 10.

Zhang Y, Hang Y, Rishi AK, Sheikh MS, Shroot B, Reichert U, Dawson MI, Poirer G, and Fontana JA. Activation of the p38 and JNK/SAPK mitogen activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Proceedings of American Association for Cancer Research, 40: 309, 1999.

Back to Internal Medicine